GALNT12 and nonpapillary renal cell carcinoma: Our research posits that CRCS1, a hypoxic variant of ccRCC demonstrated by the notable elevation of transcription factors that govern low-oxygen-adaptive genes, could see enhanced therapeutic impacts when immune checkpoints and signal transduction pathways are simultaneously inhibited.